Research Overview

In the division of Cell and Gene Therapy, our goal is to understand the regulatory control of stem and progenitor cells of the human CNS, and to utilize that knowledge to design new approaches for treating neurological diseases, primarily using cell and gene therapy. We have two principal focuses, one on the glial disorders potentially modifiable through a better understanding of glial progenitor cell biology, and the other on those neuronal disorders potentially treatable through the induction of neuronal addition or replacement from mobilized endogenous stem and progenitor cells. Our disease targets are those attributable to dysfunction or loss of single cell types; for instance, demyelinating disease is studied as a potential target for oligodendrocyte progenitor cell delivery, while Huntington’s disease is studied as a potential beneficiary of medium spiny neuronal replacement from endogenous stem cells. Conversely, gliomas and gliomagenesis are studied from the standpoint of dysregulated signaling by endogenous glial progenitors.

In regards to the glial disorders, we are targeting an expansive category that includes not only multiple sclerosis and vascular demyelination, but also the hereditary leukodystrophies and storage disorders, as well as glial neoplasms and even neuropsychiatric disorders. In particular, we have a strong focus on using cell transplantation technologies for the treatment of the glial and myelin disorders.

At the same time, we continue to study adult neurogenesis, with the goal of mobilizing endogenous progenitors in those neurodegenerative disorders potentially ameliorated by neuronal replacement. Our intent is to induce neuronal production in adults as a means of structural repair of damaged or diseased neural circuits, with the induction of medium spiny neurogenesis for cell replacement in Huntington’s Disease being prototypic.

To these various ends, we have developed a broad set of stem and progenitor cell focused technologies that have permitted us to make substantial progress on many fronts.

See all Goldman Lab Publications.

Major Lines of Investigation

To provide a basis for the lab’s translationally-oriented studies, we have established a molecular atlas of differential gene expression by human neural stem and progenitor cells of both the adult and fetal human brain. The generation of this atlas required the invention of several new techniques for phenotype-specific cell identification, FACS isolation and profiling, which comprise a coherent body of patents and papers spanning the past 15 years. Read more about developing an atlas of gene expression by human neural stem and progenitor cells

This project focuses on defining the gene expression changes during anaplastic progression of isolated glioma tumor progenitor cells, derived and isolated during tumor progression from low grade gliomas through malignant gliomas and glioblastoma. Read more about transcriptional and pathway regulation of human glial tumor stem cells

This project focuses on defining the gene expression changes associated with in vivo remyelination by human oligodendrocyte progenitor cells, using our novel human glial chimeric brain model. Read more about transcriptional events in remyelination by human oligodendrocyte progenitors

Huntington's disease is a neurodegenerative disease characterized in part by the loss of neostriatal neurons, and in particularly of medium spiny striatopallidal projection neurons. In a series of papers over the past decade, we have established BDNF and noggin over-expression as a feasible strategy by which to induce neuronal addition to the adult murine neostriatum. These observations suggest the potential feasibility of induced neurogenesis as a promising means of disease modification in HD. Read more about induing endogenous progenitors as a means of treatment in Huntingtonøs Disease

We have established human glial chimeric mice with glial progenitor cells derived from iPS cells themselves derived from patients with juvenile-onset schizophrenia, a category typically associated with a set of described mutations and copy number variants. By this means, we have generated human glial chimeric mice whose glia have been largely replaced by human glial progenitors and their derived astrocytes, in which the selective effects of schizophrenia-derived glia, on both cortical neuroanatomy and behavior may be assessed, relative to those derived from normal patient controls. Read more about use of hiPSC and hESC-derived neural progenitors for modeling neuropychiatric disease

In the most clinically-advanced of the lab’s lines of investigation, we have established protocols for the identification, isolation and transplantation of human oligodendrocyte progenitor cells, which have succeeded in completely remyelinating the nervous systems of congenitally-hypomyelinated animals and rescuing normal neurological phenotype. Read more about glial progenitor-based cell therapy in myelin disease

Sophisticated cognitive abilities, such as an unparalleled capacity for learning, language, abstract expression, and metacognition are said to set humans apart from animals. But what accounts for these differences? Classically, interspecies variation in intelligence has been attributed to neurons. However, comparisons between the brains of different species indicate that the proportional make up and sophistication of a different, historically underappreciated, type of brain cell increases as a function of increased cognitive capability. This project is a collaboration between the Goldman Lab and the Nedergaard Lab. Read more about evolutionary changes of astrocytes